Animal models have also suggested the potential biological benefit of topiramate (TPM) on AD progression, which: (1) stimulates GABAA receptor function [114]; (2) blocks AMPA receptors; (3) acts as histone deacetylase; and (4) inhibits GSK-3β, reducing the amount of hyperphosphorylated tau [23]. The gene discussed is MAPT; the disease is Alzheimer disease.